Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Research & Development (2016 - 2024)

Cytosorbents' Research & Development history spans 14 years, with the latest figure at -$640040.0 for Q4 2024.

  • Quarterly results put Research & Development at -$640040.0 for Q4 2024, down 115.62% from a year ago — trailing twelve months through Dec 2024 was $5.0 million (down 68.34% YoY), and the annual figure for FY2025 was $3.4 million, down 32.18%.
  • Research & Development for Q4 2024 was -$640040.0 at Cytosorbents, down from $1.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.1 million in Q4 2021 to a low of -$640040.0 in Q4 2024.
  • The 5-year median for Research & Development is $3.3 million (2022), against an average of $3.1 million.
  • The sharpest move saw Research & Development soared 143.07% in 2021, then crashed 115.62% in 2024.
  • Year by year, Research & Development stood at $2.7 million in 2020, then skyrocketed by 128.51% to $6.1 million in 2021, then plummeted by 44.57% to $3.4 million in 2022, then grew by 20.42% to $4.1 million in 2023, then crashed by 115.62% to -$640040.0 in 2024.
  • According to Business Quant data, Research & Development over the past three periods came in at -$640040.0, $1.9 million, and $1.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.